rocapuldencel-T

Argos finds silver lining for I/O candidate
BioPharma Dive
Tue, 11/14/17 - 07:55 pm
Argos
immuno-oncology
rocapuldencel-T
Argos’ PhIII for its personalized cancer vaccine implodes during an interim analysis
Endpoints
Wed, 02/22/17 - 09:49 am
Argos
personalized medicine
vaccines
rocapuldencel-T
renal cell carcinoma